A new trading day began on Tuesday, with Adc Therapeutics SA (NYSE: ADCT) stock price down -5.44% from the previous day of trading, before settling in for the closing price of $1.47. ADCT’s price has ranged from $1.42 to $6.04 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 88.01% over the last five years. Meanwhile, its annual earnings per share averaged 41.98%. With a float of $77.58 million, this company’s outstanding shares have now reached $96.69 million.
The firm has a total of 162 workers. Let’s measure their productivity. In terms of profitability, gross margin is 89.36%, operating margin of -196.67%, and the pretax margin is -235.56%.
Adc Therapeutics SA (ADCT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Adc Therapeutics SA is 19.76%, while institutional ownership is 69.75%. The most recent insider transaction that took place on Dec 11 ’24, was worth 304,500. In this transaction 10% Owner of this company bought 100,000 shares at a rate of $3.04, taking the stock ownership to the 15,666,731 shares. Before that another transaction happened on Dec 11 ’24, when Company’s 10% Owner bought 100,000 for $3.04, making the entire transaction worth $304,500. This insider now owns 13,145,712 shares in total.
Adc Therapeutics SA (ADCT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.22% during the next five years compared to -10.46% drop over the previous five years of trading.
Adc Therapeutics SA (NYSE: ADCT) Trading Performance Indicators
Here are Adc Therapeutics SA’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.40, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.54 in one year’s time.
Technical Analysis of Adc Therapeutics SA (ADCT)
Analysing the last 5-days average volume posted by the [Adc Therapeutics SA, ADCT], we can find that recorded value of 0.53 million was lower than the volume posted last year of 0.57 million. As of the previous 9 days, the stock’s Stochastic %D was 16.26%. Additionally, its Average True Range was 0.14.
During the past 100 days, Adc Therapeutics SA’s (ADCT) raw stochastic average was set at 0.00%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.39% in the past 14 days, which was lower than the 132.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9620, while its 200-day Moving Average is $2.9121. Now, the first resistance to watch is $1.4567. This is followed by the second major resistance level at $1.5233. The third major resistance level sits at $1.5567. If the price goes on to break the first support level at $1.3567, it is likely to go to the next support level at $1.3233. Should the price break the second support level, the third support level stands at $1.2567.
Adc Therapeutics SA (NYSE: ADCT) Key Stats
With a market capitalization of 134.40 million, the company has a total of 96,690K Shares Outstanding. Currently, annual sales are 69,560 K while annual income is -240,050 K. The company’s previous quarter sales were 18,460 K while its latest quarter income was -43,970 K.
